SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma trades in green on the bourses

08 Jul 2016 Evaluate

Aurobindo Pharma is currently trading at Rs. 774.00, up by 10.90 points or 1.43% from its previous closing of Rs. 763.10 on the BSE.

The scrip opened at Rs. 769.90 and has touched a high and low of Rs. 778.45 and Rs. 769.90 respectively. So far 39,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 891.50 on 30-Dec-2015 and a 52 week low of Rs. 582.00 on 25-Feb-2016.

Last one week high and low of the scrip stood at Rs. 778.45 and Rs. 747.20 respectively. The current market cap of the company is Rs. 45,312.61 crore.

The promoters holding in the company stood at 53.79%, while Institutions and Non-Institutions held 34.67% and 11.54% respectively.

Aurobindo Pharma is reportedly aiming to achieve $3 billion in revenues in next two years. In this regard, the company will increase number of launches in the US market. Even though Aurobindo had launched as many as 28 products in the US market in the previous year, it has carried forward 7 ANDA final approvals received during the year for the launch in the current year.

The company as on March, 2016 has filed 398 ANDAs on a cumulative basis, out of which 251 ANDAs were approved including 36 tentative approvals and balance 147 ANDAs are under review by the USFDA.

Aurobindo Pharma Share Price

1488.00 -0.50 (-0.03%)
11-May-2026 10:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1866.90
Dr. Reddys Lab 1277.10
Cipla 1339.45
Zydus Lifesciences 935.15
Lupin 2257.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×